Australia markets closed
  • ALL ORDS

    7,391.00
    +87.70 (+1.20%)
     
  • ASX 200

    7,145.60
    +81.10 (+1.15%)
     
  • AUD/USD

    0.7037
    -0.0012 (-0.17%)
     
  • OIL

    112.70
    +0.49 (+0.44%)
     
  • GOLD

    1,845.10
    +3.90 (+0.21%)
     
  • BTC-AUD

    41,492.73
    -1,847.04 (-4.26%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • AUD/EUR

    0.6659
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0973
    -0.0065 (-0.59%)
     
  • NZX 50

    11,267.39
    +60.46 (+0.54%)
     
  • NASDAQ

    11,835.62
    -40.01 (-0.34%)
     
  • FTSE

    7,389.98
    +87.24 (+1.19%)
     
  • Dow Jones

    31,261.90
    +8.77 (+0.03%)
     
  • DAX

    13,981.91
    +99.61 (+0.72%)
     
  • Hang Seng

    20,717.24
    +596.56 (+2.96%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     

Half-Year Report on the Liquidity Contract Signed by Lysogene with Kepler Cheuvreux

  • Oops!
    Something went wrong.
    Please try again later.
·10-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

PARIS, January 05, 2022--(BUSINESS WIRE)--Regulatory News:

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.

Under the liquidity contract concluded by LYSOGENE with the Kepler Cheuvreux brokerage firm, as of 31 December 2021, the following assets were held in the liquidity contract:

- Number of shares: 53,573
- Cash balance: € 115,539.70
- Number of executions on buy side on the second half: 224
- Number of executions on sell side on the second half: 216
- Traded volume on buy side on semester: 67,249 shares for € 142,998.52
- Traded volume on sell side on semester: 57,255 shares for € 126,782.42

As a reminder, as of 30 June 2021, the following assets were held in the liquidity contract:

- Number of shares: 43,579
- Cash balance: € 132,063.33
- Number of executions on buy side on semester: 369
- Number of executions on sell side on semester: 399
- Traded volume on buy side on semester: 125,130 shares for € 358,888.31
- Traded volume on sell side on semester: 131,937 shares for € 400,135.60

As a reminder, at the time of the implementation of the liquidity contract, the following assets were held in the liquidity contract:

- Number of shares: 34,030
- Cash balance: € 78,185.94

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Buy Side

Sell Side

Number of

Number of

Traded volume in
EUR

Number of

Number of

Traded volume in
EUR

executions

shares

executions

shares

Total

224

67,249

142,998.52

216

57,255

126,782.42

1/7/2021

2

1,000

2,230.00

-

-

-

2/7/2021

2

500

1,130.00

-

-

-

5/7/2021

-

-

-

3

800

1,856.00

6/7/2021

-

-

-

2

200

470

7/7/2021

1

300

690

6

500

1,200.00

8/7/2021

10

3,200

6,848.00

-

-

-

9/7/2021

-

-

-

15

4,943

12,110.35

12/7/2021

4

1,500

3,450.00

4

1,000

2,450.00

13/07/2021

3

1,500

3,300.00

6

2,285

5,232.65

14/07/2021

-

-

-

5

1,715

4,270.35

16/07/2021

1

1

2.41

1

1

2.41

19/07/2021

14

6,500

14,170.00

1

500

1,205.00

20/07/2021

-

-

-

3

1,000

2,180.00

21/07/2021

1

500

1,075.00

1

500

1,125.00

22/07/2021

3

500

1,075.00

2

500

1,125.00

23/07/2021

4

1,000

2,160.00

-

-

-

28/07/2021

1

500

1,050.00

-

-

-

29/07/2021

1

500

1,025.00

1

500

1,065.00

30/07/2021

3

1,000

2,010.00

-

-

-

2/8/2021

-

-

-

3

500

1,025.00

3/8/2021

-

-

-

1

500

1,050.00

4/8/2021

1

500

1,020.00

-

-

-

5/8/2021

1

500

1,000.00

-

-

-

6/8/2021

-

-

-

2

500

1,035.00

10/8/2021

1

1

2.02

1

1

2.02

17/08/2021

1

1

2

1

1

2

18/08/2021

1

1

2.02

1

1

2.02

19/08/2021

-

-

-

1

500

1,050.00

25/08/2021

1

500

1,000.00

6

2,500

5,500.00

26/08/2021

1

500

1,100.00

-

-

-

27/08/2021

-

-

-

1

500

1,150.00

30/08/2021

-

-

-

11

3,500

8,540.00

31/08/2021

1

500

1,200.00

-

-

-

1/9/2021

-

-

-

10

2,000

5,260.00

2/9/2021

13

5,995

15,047.45

2

236

637.2

3/9/2021

-

-

-

2

1,000

2,530.00

6/9/2021

1

500

1,225.00

-

-

-

9/9/2021

3

1,000

2,380.00

-

-

-

10/9/2021

4

1,500

3,480.00

-

-

-

13/09/2021

3

1,000

2,280.00

-

-

-

15/09/2021

-

-

-

1

1

2.3

16/09/2021

-

-

-

2

499

1,147.70

17/09/2021

1

500

1,125.00

-

-

-

20/09/2021

7

2,000

4,360.00

-

-

-

Buy Side

Sell Side

Number of

Number of

Traded volume in EUR

Number of

Number of

Traded volume in EUR

executions

shares

executions

shares

Total

224

67,249

142,998.52

216

57,255

126,782.42

21/09/2021

2

501

1,057.11

1

1

2.11

22/09/2021

-

-

-

9

1,500

3,375.00

23/09/2021

-

-

-

2

500

1,175.00

24/09/2021

4

1,500

3,375.00

-

-

-

27/09/2021

-

-

-

2

913

2,099.90

28/09/2021

1

500

1,100.00

1

1

2.3

29/09/2021

1

500

1,100.00

-

-

-

30/09/2021

2

100

218

-

-

-

1/10/2021

2

500

1,075.00

-

-

-

8/10/2021

4

401

854.13

1

1

2.13

11/10/2021

11

3,500

7,105.00

-

-

-

12/10/2021

3

500

1,000.00

1

500

1,025.00

13/10/2021

1

500

1,000.00

-

-

-

14/10/2021

-

-

-

1

500

1,025.00

20/10/2021

-

-

-

1

500

1,050.00

22/10/2021

1

1

2.12

1

1

2.12

25/10/2021

8

1,000

2,070.00

-

-

-

26/10/2021

1

500

1,000.00

-

-

-

27/10/2021

-

-

-

6

1,500

3,150.00

28/10/2021

4

1,500

3,075.00

-

-

-

1/11/2021

6

1,500

3,270.00

10

2,586

5,870.22

2/11/2021

1

500

1,050.00

1

500

1,100.00

3/11/2021

6

500

1,050.00

3

340

765

4/11/2021

4

1,500

3,000.00

-

-

-

9/11/2021

2

1,000

1,980.00

-

-

-

12/11/2021

-

-

-

1

500

1,000.00

15/11/2021

2

500

975

-

-

-

16/11/2021

1

1

1.98

1

1

1.98

17/11/2021

-

-

-

1

81

162

18/11/2021

3

500

975

1

419

838

19/11/2021

5

1,001

1,881.88

5

501

951.9

22/11/2021

1

1

1.84

-

-

-

26/11/2021

2

500

900

6

1,000

1,930.00

29/11/2021

-

-

-

2

500

970

30/11/2021

6

1,500

2,730.00

-

-

-

1/12/2021

-

-

-

4

500

900

2/12/2021

1

500

875

-

-

-

6/12/2021

-

-

-

3

1,000

1,880.00

7/12/2021

3

700

1,267.00

5

1,200

2,304.00

8/12/2021

4

600

1,140.00

1

1

1.96

9/12/2021

2

201

381.9

2

200

392

10/12/2021

2

200

378

-

-

-

13/12/2021

1

200

400

8

2,700

5,535.00

14/12/2021

5

1,500

3,000.00

-

-

-

15/12/2021

2

500

985

7

2,623

5,455.84

Buy Side

Sell Side

Number of

Number of

Traded volume in EUR

Number of

Number of

Traded volume in EUR

executions

shares

executions

shares

Total

224

67,249

142,998.52

216

57,255

126,782.42

16/12/2021

4

500

1,025.00

1

500

1,050.00

17/12/2021

7

2,001

3,961.98

1

1

2.04

20/12/2021

2

839

1,678.00

10

3,500

7,175.00

21/12/2021

2

1,000

1,920.00

-

-

-

22/12/2021

2

2

3.8

-

-

-

23/12/2021

5

1,501

2,821.88

1

1

1.9

24/12/2021

1

500

1,000.00

20

6,000

12,360.00

27/12/2021

1

500

995

-

-

-

28/12/2021

2

1,000

1,960.00

1

1

2.02

29/12/2021

3

500

970

-

-

-

30/12/2021

1

500

950

-

-

-

About Lysogene
Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive clinical trial in GM1 gangliosidosis is ongoing. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene has also entered into an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate for the treatment of the Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Forward Looking Statement
This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products, and (vi) a modification of the terms of its agreements with Sarepta Therapeutics. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "objective", "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005603/en/

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting